AR093806A1 - Derivados de piridina agonistas de receptores cb2 - Google Patents
Derivados de piridina agonistas de receptores cb2Info
- Publication number
- AR093806A1 AR093806A1 ARP130104506A ARP130104506A AR093806A1 AR 093806 A1 AR093806 A1 AR 093806A1 AR P130104506 A ARP130104506 A AR P130104506A AR P130104506 A ARP130104506 A AR P130104506A AR 093806 A1 AR093806 A1 AR 093806A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenylalkyl
- heptyl
- alkyl
- azabicyclo
- oxa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), en la que: R¹ es cicloalquilalcoxi, halofenilo, tetrahidrofuranilalcoxi, halofenilalquilo, haloalquiloxi, alquilsulfonilo, tetrahidropiranilalcoxi o halógeno; R² es alquilo, pirrolidinilo, cicloalquilo, haloazetidinilo, haloalquilo, cicloalquilalcoxi, haloalquiloxi, halocicloalquilo, hidroxicicloalquilo o halooxetanilo; uno de R³ y R⁴ es alquilo, cicloalquilo, haloalquilo o hidroxialquilo y el otro es alquilo, alquiloxialquilo, (haloazetidinil)(cicloalquiloxi)piridinilcarboniloxialquilo haloalquilcicloalquilo, hidroxialquilo, fenilalquilo, alcoxicarbonilalquilo, carboxialquilo, alquilaminocarbonilalquilo, (alquiloxadiazolil)(cicloalquilalquil)alquilo, (alquiloxadiazolil)(cicloalquil)alquilo, piridazinilalquilo, aminocarbonilalquilo, alquiloxadiazolilalquilo, alquiltetrazolilalquilo, formilo, fenilo, dialquilpirazolilo, alquilcarbonilpiperidinilo o cicloalquilalquilo; o R³ y R⁴ junto con el átomo de nitrógeno, al que están unidos, forman un heterociclilo o heterociclilo sustituido; dicho heterociclilo es el 6-oxa-1-aza-espiro[3.3]heptilo, oxazolidinilo, morfolinilo, pirrolidinilo, piperazinilo, 2-oxa-5-aza-espiro[3.4]octilo piperidinilo, 6-azabiciclo-[3.2.1]octilo, imidazolidinilo, 4-azaespiro[2.4]heptilo, 2-azabiciclo[2.2.1]heptilo, 2-tia-5-azabiciclo[2.2.1]heptilo, 2,5-diazabiciclo[2.2.1]heptilo, 2-oxa-5-azabiciclo[2.2.1]-heptilo, hexahidrofuro[2,3-c]pirrolilo, 2-tia-6-azaespiro-[3.3]heptilo, 1,8-diaza-espiro[4.5]decilo, 1-oxa-7-azaespiro-[4.4]nonilo, 5-oxa-2-aza-espiro[3.4]octilo, 8-oxa-3-azabiciclo[3.2.1]octilo, 3-oxa-8-azabiciclo[3.2.1]octilo, tiomorfolinilo, tiazolidinilo, 5-azaespiro[3.4]octilo, azetidinilo, 5-aza-espiro[2.4]heptilo, 3-azabiciclo[3.1.0]-hexilo o 5-aza-espiro[2.4]heptilo, 1,3,3a,4,6,6a-hexahidrofuro[3,4-c]-pirrolilo; y dicho heterociclilo sustituido es un heterociclilo sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre alquilo, oxo, hidroxilo, carboxilo, alquilcarbonilamino, alquiloxialquilo, hidroxialquilo, aminocarbonilo, halógeno, fenilalquilo, fenilo, alcoxicarbonilo, cicloalquilalquilo, fenilalcoxicarbonilo, cicloalquilo, halohidroxialquilo y haloalquilo; con la condición de que R³ y R⁴ junto con el átomo de nitrógeno, al que están unidos, no formen un piperidinilo sin sustituir, un tiomorfolinilo sin sustituir ni un hidroxialquilpirrolidinilo; o una sal o un éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12196032 | 2012-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093806A1 true AR093806A1 (es) | 2015-06-24 |
Family
ID=47290808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104506A AR093806A1 (es) | 2012-12-07 | 2013-12-05 | Derivados de piridina agonistas de receptores cb2 |
Country Status (32)
Country | Link |
---|---|
US (1) | US9303012B2 (es) |
EP (1) | EP2928868B1 (es) |
JP (1) | JP6426619B2 (es) |
KR (1) | KR20150091080A (es) |
CN (1) | CN104854092B (es) |
AR (1) | AR093806A1 (es) |
AU (1) | AU2013354114B2 (es) |
BR (1) | BR112015009600A2 (es) |
CA (1) | CA2885987A1 (es) |
CL (1) | CL2015001538A1 (es) |
CR (1) | CR20150204A (es) |
DK (1) | DK2928868T3 (es) |
EA (1) | EA025841B1 (es) |
ES (1) | ES2643058T3 (es) |
HK (1) | HK1208033A1 (es) |
HR (1) | HRP20171445T1 (es) |
IL (1) | IL237988A (es) |
LT (1) | LT2928868T (es) |
MA (2) | MA40308A1 (es) |
MX (1) | MX2015007033A (es) |
MY (1) | MY182328A (es) |
PE (1) | PE20151089A1 (es) |
PH (1) | PH12015501073A1 (es) |
PL (1) | PL2928868T3 (es) |
PT (1) | PT2928868T (es) |
RS (1) | RS56423B1 (es) |
SG (1) | SG11201504122YA (es) |
SI (1) | SI2928868T1 (es) |
TW (1) | TWI617551B (es) |
UA (1) | UA114655C2 (es) |
WO (1) | WO2014086806A1 (es) |
ZA (1) | ZA201502872B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102369407B1 (ko) | 2013-03-07 | 2022-03-02 | 에프. 호프만-라 로슈 아게 | 신규 피라졸 유도체 |
SI2978755T1 (en) | 2013-03-26 | 2018-03-30 | F. Hoffmann-La Roche Ag | New pyridine derivatives |
PE20151977A1 (es) | 2013-05-02 | 2016-01-07 | Hoffmann La Roche | Nuevos derivados de purina |
HUE035333T2 (en) | 2013-05-02 | 2018-05-02 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
RS58390B1 (sr) | 2013-09-06 | 2019-04-30 | Hoffmann La Roche | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora |
EA030032B1 (ru) * | 2014-04-04 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов |
AR099933A1 (es) * | 2014-04-04 | 2016-08-31 | Hoffmann La Roche | Derivados heterocíclicos de piridina agonistas de cb2 |
WO2016121959A1 (ja) * | 2015-01-30 | 2016-08-04 | 富士フイルム株式会社 | イソインドリン化合物またはその塩の製造方法および新規イソインドリン化合物またはその塩 |
SI3386951T1 (sl) | 2015-12-09 | 2020-07-31 | F. Hoffmann-La Roche Ag | Fenilni derivati kot agonisti kanabinoidnega receptorja 2 |
CN106187910A (zh) * | 2016-07-07 | 2016-12-07 | 浙江大学 | 哒嗪类衍生物及其制备方法和用途 |
CN110753690B (zh) | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
EP3814329B1 (en) * | 2018-06-27 | 2024-01-17 | F. Hoffmann-La Roche AG | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
EP3814337A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2076499B1 (en) * | 2006-10-04 | 2010-05-12 | F.Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
-
2013
- 2013-12-04 BR BR112015009600A patent/BR112015009600A2/pt not_active Application Discontinuation
- 2013-12-04 ES ES13799544.5T patent/ES2643058T3/es active Active
- 2013-12-04 CA CA 2885987 patent/CA2885987A1/en not_active Abandoned
- 2013-12-04 EA EA201590854A patent/EA025841B1/ru not_active IP Right Cessation
- 2013-12-04 MA MA40308A patent/MA40308A1/fr unknown
- 2013-12-04 SI SI201330793T patent/SI2928868T1/sl unknown
- 2013-12-04 RS RS20171007A patent/RS56423B1/sr unknown
- 2013-12-04 MX MX2015007033A patent/MX2015007033A/es unknown
- 2013-12-04 PL PL13799544T patent/PL2928868T3/pl unknown
- 2013-12-04 CN CN201380063631.1A patent/CN104854092B/zh not_active Expired - Fee Related
- 2013-12-04 LT LTEP13799544.5T patent/LT2928868T/lt unknown
- 2013-12-04 MY MYPI2015701834A patent/MY182328A/en unknown
- 2013-12-04 US US14/648,418 patent/US9303012B2/en active Active
- 2013-12-04 EP EP13799544.5A patent/EP2928868B1/en not_active Not-in-force
- 2013-12-04 AU AU2013354114A patent/AU2013354114B2/en not_active Ceased
- 2013-12-04 WO PCT/EP2013/075443 patent/WO2014086806A1/en active Application Filing
- 2013-12-04 SG SG11201504122YA patent/SG11201504122YA/en unknown
- 2013-12-04 JP JP2015545792A patent/JP6426619B2/ja not_active Expired - Fee Related
- 2013-12-04 UA UAA201506100A patent/UA114655C2/uk unknown
- 2013-12-04 MA MA38218A patent/MA38218A1/fr unknown
- 2013-12-04 KR KR1020157014988A patent/KR20150091080A/ko not_active Application Discontinuation
- 2013-12-04 DK DK13799544.5T patent/DK2928868T3/en active
- 2013-12-04 PE PE2015000754A patent/PE20151089A1/es not_active Application Discontinuation
- 2013-12-04 PT PT137995445T patent/PT2928868T/pt unknown
- 2013-12-05 AR ARP130104506A patent/AR093806A1/es unknown
- 2013-12-06 TW TW102144981A patent/TWI617551B/zh not_active IP Right Cessation
-
2015
- 2015-03-26 IL IL237988A patent/IL237988A/en not_active IP Right Cessation
- 2015-04-20 CR CR20150204A patent/CR20150204A/es unknown
- 2015-04-28 ZA ZA2015/02872A patent/ZA201502872B/en unknown
- 2015-05-14 PH PH12015501073A patent/PH12015501073A1/en unknown
- 2015-06-05 CL CL2015001538A patent/CL2015001538A1/es unknown
- 2015-09-08 HK HK15108721.2A patent/HK1208033A1/xx not_active IP Right Cessation
-
2017
- 2017-09-26 HR HRP20171445TT patent/HRP20171445T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093806A1 (es) | Derivados de piridina agonistas de receptores cb2 | |
AR093804A1 (es) | Derivados de pirazina agonistas de receptores cb2 | |
AR109471A1 (es) | Compuestos útiles como inmunomoduladores | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
AR096152A1 (es) | Derivados de purina | |
AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR093843A1 (es) | Derivados de piridina agonistas de receptores cb2 | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
AR110405A1 (es) | Compuestos | |
AR088970A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
AR066502A1 (es) | Compuestos amino- heterociclicos | |
IN2015MN00464A (es) | ||
AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
AR086881A1 (es) | Derivados de picolinamida como agonistas del receptor cb2 | |
AR099932A1 (es) | Derivados de piridina | |
AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
AR092973A1 (es) | Benzamidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |